Active ingredientPalovaroteneCat. No. P-P007-001CAS 410528-02-8Family · Pharmaceutical analytical standards
Palovarotene
An oral retinoid, a selective retinoic acid receptor gamma agonist, approved in 2022 in Canada and in 2023 in the United States as the first therapy for fibrodysplasia ossificans progressiva, a rare disease in which muscle turns into bone. This family brings together the active ingredient and labelled standards.
Did you know?Before reaching this disease, which affects about one person in two million, it had been studied in more than 800 people, including patients with chronic obstructive pulmonary disease and emphysema.
Go to the active ingredient →Active ingredientPalovaroteneCat. No. P-P007-001CAS 410528-02-8
Isotopically labelledPalovarotene-d4Cat. No. P-P007-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.